EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing in silico drug discovery: simulation of connected differential expression signatures and applications to benchmarking

Catalina Gonzalez Gomez iD, Manuel Rosa-Calatrava, Julien Fouret iD

Briefings in Bioinformatics · 2024

DOI: 10.1093/bib/bbae299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, 2024. Verfasst von Catalina Gonzalez Gomez und 2 weiteren Autor:innen. Beteiligte Einrichtung: CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, 14 Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308,…. Hauptthemen laut MEDLINE: Benchmarking, Drug Discovery, Algorithms, Computer Simulation. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French National Research and Technology Agency, CIFRE, H2020 EIC Accelerator Instrument.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We present a novel simulation method for generating connected differential expression signatures. Traditional methods have struggled with the lack of reliable benchmarking data and biases in drug–disease pair labeling, limiting the rigorous benchmarking of connectivity-based approaches.

Objective

Our aim is to develop a simulation method based on a statistical framework that allows for adjustable levels of parametrization, especially the connectivity, to generate a pair of interconnected differential signatures. This could help to address the issue of benchmarking data availability for connectivity-based drug repurposing approaches.

Methods

We first detailed the simulation process and how it reflected real biological variability and the interconnectedness of gene expression signatures. Then, we generated several datasets to enable the evaluation of different existing algorithms that compare differential expression signatures, providing insights into their performance and limitations.

Results

Our findings demonstrate the ability of our simulation to produce realistic data, as evidenced by correlation analyses and the log2 fold-change distribution of deregulated genes. Benchmarking reveals that methods like extreme cosine similarity and Pearson correlation outperform others in identifying connected signatures.

Conclusion

Overall, our method provides a reliable tool for simulating differential expression signatures. The data simulated by our tool encompass a wide spectrum of possibilities to challenge and evaluate existing methods to estimate connectivity scores. This may represent a critical gap in connectivity-based drug repurposing research because reliable benchmarking data are essential for assessing and advancing in the development of new algorithms. The simulation tool is available as a R package (General Public License (GPL) license) at https://github.com/cgonzalez-gomez/cosimu.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenchmarkingDrug DiscoveryAlgorithmsComputer SimulationHumansGene Expression ProfilingComputational BiologyDrug RepositioningTranscriptome

Stichwörter der Autor:innen

benchmarkingconnectivity scoredifferential expression signaturedrug repurposingsimulation tool

Autor:innen und Institutionen

  • CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, 14 Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-15 69007 Lyon, Rhône-Alpes, France.
  • International Associated Laboratory RespiVir France-Canada, Centre de Recherche en Infectiologie, Faculté de Médecine RTH Laennec 69008 Lyon, Université Claude Bernard Lyon 1, Université de Lyon, INSERM, CNRS, ENS de Ly…
  • Nexomis, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, 7 Rue Guillaume Paradin, 69008 Lyon, Rhône-Alpes, France.
  • Signia Therapeutics, 60 Avenue Rockefeller, 69008 Lyon, Rhône-Alpes, France.
  • VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, 7 Rue Guillaume Paradin, 69008 Lyon, Rhône-Alpes, France.

ORCID-Profile: Catalina Gonzalez Gomez, Julien Fouret

Förderung

  • French National Research and Technology Agency
  • CIFRE
  • H2020 EIC Accelerator Instrument
  • European Commission

Zitieren

APA

Gonzalez Gomez, C., Rosa-Calatrava, M., & Fouret, J. (2024). Optimizing in silico drug discovery: simulation of connected differential expression signatures and applications to benchmarking. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbae299

Vancouver

Gonzalez Gomez C, Rosa-Calatrava M, Fouret J. Optimizing in silico drug discovery: simulation of connected differential expression signatures and applications to benchmarking. Briefings in Bioinformatics. 2024. doi:10.1093/bib/bbae299

BibTeX
@article{GonzalezGomez2024,
  author = {Gonzalez Gomez, Catalina and Rosa-Calatrava, Manuel and Fouret, Julien},
  title = {Optimizing in silico drug discovery: simulation of connected differential expression signatures and applications to benchmarking},
  journal = {Briefings in Bioinformatics},
  year = {2024},
  doi = {10.1093/bib/bbae299}
}
Kostenlos starten →